Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

NCT00697632 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
180
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Mirati Therapeutics Inc.